Phase 3 CERVINO results show that monthly etentamig significantly improved PFS and response rates compared with investigator-selected therapy in patients with previously treated multiple myeloma.
|Articles|December 20, 2013
Jatin J. Shah, MD Discusses Novel Therapies for Multiple Myeloma
In this OncLive video, Jatin J. Shah, MD, assistant professor in lymphoma/myeloma in the Division of Cancer Medicine at the University of Texas, MD Anderson Cancer Center, discusses novel therapeutics for the treatment of multiple myeloma.
Advertisement
In this OncLive video, Jatin J. Shah, MD, assistant professor in lymphoma/myeloma in the Division of Cancer Medicine at the University of Texas, MD Anderson Cancer Center, discusses novel therapeutics for the treatment of multiple myeloma.
Jatin J. Shah, MD, speaks about therapies that have become available in recent years for the treatment of patients with multiple myeloma in this OncLive video. Click
Advertisement
Related to this article
The randomized ALLIANCE A051701 trial closed early when treatment-related toxicity and mortality were increased without improving PFS in patients with newly diagnosed double-hit lymphoma.
With changes in Medicaid eligibility looming, hospitals must plan now to keep patient care gaps at bay.
Investigational antiamyloid monoclonal antibodies may offer a novel pathway to disease reversal.
Increasingly, pharmacists are leading the obesity management team.
HYPERION trial data now support sotatercept within a patient's first year of pulmonary arterial hypertension (PAH) diagnosis, cutting clinical worsening risk by 76% compared with placebo.
A stewardship program combining EHR alerts and pharmacist-led education offers a replicable model for reducing bleeding risk.
A panel of cardiology pharmacists discussed the diagnostic red flags, evolving treatment landscape, and expanding pharmacist role central to identifying and managing ATTR-CM.
Advertisement
Advertisement
Trending on Pharmacy Times
1
New Data Reshapes Nonstatin Lipid Therapy Choices
2
Eight Names, One Drug: Why Adalimumab Biosimilars Are Creating Real Confusion at the Counter
3
Etentamig Reduces Risk of Progression or Death by 60% in Relapsed/Refractory Multiple Myeloma
4
Community Pharmacy Must Pair Trust With Digital Convenience
5